Resolutions from the Annual General Meeting 2023 in Pharmacolog i Uppsala
The English translation of the resolutions is an unofficial translation of the Swedish original. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
The shareholders of Pharmacolog i Uppsala AB (publ) held the Annual General Meeting on June 30, 2023 in Uppsala.
Annual report and results
The annual report and auditor's report were presented and the income statement and balance sheet were adopted. It was decided to dispose of the company's earnings in accordance with the Board's proposal.
Discharge from liability
The Annual General Meeting resolved to discharge the members of the Board of Directors and the CEO from liability.
Fees
The Board fee was set at SEK 150,000 to the Chairman and SEK 100,000 each to the other Board members. Remuneration to the company's auditor was resolved to be paid in accordance with current accounts.
Board
The Annual General Meeting resolved to re-elect Erik Hedlund and Ragnar Linder and to elect Anders Hedlund and Henrik Magnusson Hjorth as new members. Erik Hedlund was also re-elected as Chairman of the Board.
Auditor and deputy auditor
The Annual General Meeting resolved to re-elect Folkesson Råd & Revision AB as auditor until the end of the next Annual General Meeting with approved auditor Sten Eriksson as auditor in charge.
Issue authorizations
The Annual General Meeting resolved to authorize the Board of Directors, on one or more occasions, for the period until the next Annual General Meeting, to resolve to increase the company's share capital up to the limit for share capital according to the Articles of Association that exists the first time the issue authorization is exercised. The authorization may be used to issue shares, warrants and/or convertibles. If the Board of Directors exercises the authorization, it may also be done with deviation from the shareholders' preferential rights and/or with provisions for non-cash issue or set-off.
For more information contact:
Lars Gusch, CEO
Email: lars.gusch@pharmacolog.com
Phone: +46 70-223 97 72
About Pharmacolog
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, DrugLog™, WasteLog™, PrepLog™ and Pharmacolog Dashboard™.
Further information regarding the company is available at https://pharmacolog.com/.
The company's Certified Adviser is Mangold Fondkommission AB.
Tags:
